Javascript must be enabled to continue!
Formulation And Evaluation of Lipo-Nanosphere Loaded Docetaxel Drug
View through CrossRef
As nanotechnology advances, the nanoliposphere is being considered as a possible drug carrier to enhance the bioavailability of some lipophilic drugs. Lipospheres are often employed to deliver hydrophobic agents because lipids can make pharmaceuticals more soluble and release them in a controlled manner. Antineoplastic medication docetaxel (DCX) is useful for treating a variety of complicated malignancies, particularly cancers of the breast and ovary. Because it is highly hydrophobic, low bioavailability due to the extreme toxicity of DCX, it was only developed for intravenous infusion on the market at a dose of 100 mg/m every three weeks (Taxotere®). The creation of lipo-nanospheres (LPNS) as docetaxel carriers is discussed in this work. The synthesized lipo-nanospheres, which are made of biodegradable and bio-acceptable lipids, are described for surface morphology, crystallinity, and release studies. This accomplished by Fourier transform infrared spectroscopy (FTIR), polydispersity index, particle size, and in vitro release studies
Due to delayed drug diffusion from lipo-nanospheres, docetaxel's in vitro release behaviors from the created lipo-nanospheres showed a biphasic pattern, with a quick initial release and a slower, continuous release over the course of 24 hours. Our findings show that the created formulation of lipo-nanospheres containing docetaxel can be effective against complicated malignancies.
College of Pharmacy University of Baghdad
Title: Formulation And Evaluation of Lipo-Nanosphere Loaded Docetaxel Drug
Description:
As nanotechnology advances, the nanoliposphere is being considered as a possible drug carrier to enhance the bioavailability of some lipophilic drugs.
Lipospheres are often employed to deliver hydrophobic agents because lipids can make pharmaceuticals more soluble and release them in a controlled manner.
Antineoplastic medication docetaxel (DCX) is useful for treating a variety of complicated malignancies, particularly cancers of the breast and ovary.
Because it is highly hydrophobic, low bioavailability due to the extreme toxicity of DCX, it was only developed for intravenous infusion on the market at a dose of 100 mg/m every three weeks (Taxotere®).
The creation of lipo-nanospheres (LPNS) as docetaxel carriers is discussed in this work.
The synthesized lipo-nanospheres, which are made of biodegradable and bio-acceptable lipids, are described for surface morphology, crystallinity, and release studies.
This accomplished by Fourier transform infrared spectroscopy (FTIR), polydispersity index, particle size, and in vitro release studies
Due to delayed drug diffusion from lipo-nanospheres, docetaxel's in vitro release behaviors from the created lipo-nanospheres showed a biphasic pattern, with a quick initial release and a slower, continuous release over the course of 24 hours.
Our findings show that the created formulation of lipo-nanospheres containing docetaxel can be effective against complicated malignancies.
Related Results
Efficacy and Safety Analysis of Combination Therapy Based on Liposomal Mitoxantrone (Lipo-MIT) in Relapsed/Refractory NK/T-Cell Lymphoma
Efficacy and Safety Analysis of Combination Therapy Based on Liposomal Mitoxantrone (Lipo-MIT) in Relapsed/Refractory NK/T-Cell Lymphoma
Background: Currently, there is no standard treatment for relapsed/refractory NK/T-cell lymphoma (NKTCL), which is characterized by highly aggressive and poor prognosis. New drugs ...
Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.
Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.
Abstract
Background: IFI remain an important cause of morbidity and mortality in pts with acute myelogenous leukemia or high risk myelodysplastic syndrome (AML/HR-MD...
Docetaxel in older patients for metastatic prostate cancer.
Docetaxel in older patients for metastatic prostate cancer.
187 Background: Docetaxel use has led to a significant prolongation in overall survival in metastatic prostate cancer (MPC). There is however limited information on treatment tole...
CXC chemokine receptor 4 is essential for Lipo‐PGE1–enhanced migration of human dermal fibroblasts
CXC chemokine receptor 4 is essential for Lipo‐PGE1–enhanced migration of human dermal fibroblasts
Abstract: Lipo‐PGE1 [EGLANDIN®; a lipid microsphere‐incorporated prostaglandin E1 (PGE1)] stimulates angiogenesis and promotes the healing of skin ulcers. Because the effects of L...
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
298 Background: Docetaxel use has led to a significant prolongation in overall survival (OS) in metastatic prostate cancer after castrate resistance, with a more substantial OS ga...
Evaluation the effects of lipo-prostaglandin E1 on older patients with chronic heart failure by 6 min walk test
Evaluation the effects of lipo-prostaglandin E1 on older patients with chronic heart failure by 6 min walk test
Objective
To evaluate the clinical effects of lipo-prostaglandin E1 on patients with chronic heart failure (CHF) by 6 min walk test (6MWT).
...
Enhanced quasi-monoenergetic ions generation: Based on gold nanoparticles application in gas-filled nanosphere targets
Enhanced quasi-monoenergetic ions generation: Based on gold nanoparticles application in gas-filled nanosphere targets
It was recently shown that nanostructured targets with largely spaced gold ultrasmall nanoparticles (NPs) show outstanding performances in enhancing the laser-driven ions' accelera...
Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer
Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer
AbstractDocetaxel is the widely-used first-line therapy to treat lung cancer around the world. However, tumor progression and severe side effect occurred in some patients with doce...

